Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec;9(23):e018143.
doi: 10.1161/JAHA.120.018143. Epub 2020 Nov 16.

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial

Alexandra Maria Rüger  1 , Andreas Schneeweiss  2 , Sabine Seiler  3 , Hans Tesch  4 , Marion van Mackelenbergh  5 , Frederik Marmé  6 , Kristina Lübbe  7 , Bruno Sinn  8 , Thomas Karn  9 , Elmar Stickeler  10 , Volkmar Müller  11 , Christian Schem  12 , Carsten Denkert  13 , Peter A Fasching  14 , Valentina Nekljudova  3 , Tania Garfias-Macedo  15   16 , Gerd Hasenfuß  15   16 , Wilhelm Haverkamp  1 , Sibylle Loibl  3 , Stephan von Haehling  15   16
Affiliations
Clinical Trial

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial

Alexandra Maria Rüger et al. J Am Heart Assoc. 2020 Dec.

Abstract

Background Patients with breast cancer can be affected by cardiotoxic reactions through cancer therapies. Cardiac biomarkers, like NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin T, might have predictive value. Methods and Results Echocardiography, ECG, hemodynamic parameters, NT-proBNP and high-sensitivity cardiac troponin T were assessed in 853 patients with early-stage breast cancer randomized in the German Breast Group GeparOcto-GBG 84 phase III trial. Patients received neo-adjuvant dose-dense, dose-intensified epirubicin, paclitaxel, and cyclophosphamide (iddEPC group, n=424) or paclitaxel, non-pegylated doxorubicin, and in triple negative breast cancer, (paclitaxel, non-pegylated doxorubicin, carboplatin group, n=429) treatment for 18 weeks. Patients positive for human epidermal growth receptor 2 (n=354, 41.5%) received monoclonal antibodies on top of allocated therapy; 119 (12.9%) of all patients showed a cardiotoxic reaction during therapy (15 [1.8%] using a more strict definition). Presence of cardiotoxic reactions was irrespective of treatment allocation (P=0.31). Small but significant increases in NT-proBNP developed early in patients with a cardiotoxic reaction as compared with those without in whom NT-proBNP rose only towards the end of therapy (P=0.04). High-sensitivity cardiac troponin T rose early in both groups. Logistic regression showed that NT-proBNP (odds ratio [OR], 1.03; 95% CI, 1.008-1.055; P=0.01) and hemoglobin (OR, 1.31; 95% CI, 1.05-1.63; P=0.02) measured at 6 weeks after treatment initiation were significantly associated with cardiotoxic reactions. Conclusions NT-proBNP and hemoglobin are significantly associated with cardiotoxic reactions in patients with early-stage breast cancer undergoing dose-dense and dose-intensified chemotherapy, but high-sensitivity cardiac troponin T is not. Registration URL: http://www.clinicaltrials.gov; Unique identifier: NCT02125344.

Keywords: biomarker; breast cancer; cardiotoxicity; cardio‐oncology; left ventricular ejection fraction.

PubMed Disclaimer

Conflict of interest statement

Denkert holds stock interests with Sividon Diagnostics and patents of VMScope and received honoraria from Celgene, Teva, Novartis, Pfizer, MSD, Amgen, and Roche. Tesch received honoraria from Novartis and Roche. Loibl received research funding from Pfizer, Sanofi, Amgen, Roche, Novartis, Celgene, Teva, Astra Zeneca, Myriad, AbbVie, Vifor, and Sividon Diagnostics. von Haehling received honoraria from BRAHMS, Roche, and Vifor. Schem received honoraria from Astra Zeneca and Roche. Fasching received honoraria from Amgen, Novartis, Pfizer, Celgene, Roche, Teva, and Astra Zeneca. Schneeweiss received honoraria from Roche, Astra Zeneca, Celgene, Pfizer, Amgen, and Novartis. Marmé received honoraria from AstraZeneca, Amgen, CureVec, Celgene, Clovis Oncology, Eisai, Genomic Health, Novartis, MSD, Pfizer, Roche, and Tesaro. van Mackelenbergh received honoraria from AstraZeneca, Amgen, Lily, Genomic Health, and Novartis. Rüger is also employed by Vifor. Lübbe received honoraria from Lily, Roche, Novartis, Genomic Health, and Pfizer. Müller received honoraria from Amgen, Astra Zeneca, Daiichi‐Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seattle Genetics, Genomic Health, Hexal, Roche, Pierre Fabre, ClinSol, Lilly, Tesaro, Nektar, and Genentech. Seiler received honoraria from Amgen, Hexal, Roche, Novartis, and Mundipharma. The remaining authors have no disclosures to report.

Figures

Figure 1
Figure 1. Study design GeparOcto‐GBG 84 trial (phase III).
HER2 indicates human epidermal growth receptor 2; iddEPC, neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide; NPLD, non‐pegylated doxorubicin; R, randomization; and PM(Cb), paclitaxel, non‐pegylated doxorubicin, carboplatin.
Figure 2
Figure 2. Consort statement GeparOcto‐GBG 84 trial (phase III).
iddEPC indicates neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide; and PM(Cb), paclitaxel, non‐pegylated doxorubicin, carboplatin.
Figure 3
Figure 3. NT‐proBNP during therapy.
A, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) (cardiotoxicity vs non‐cardiotoxicity), (B) NT‐proBNP (neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide vs paclitaxel, non‐pegylated doxorubicin, carboplatin). NT‐proBNP as assessed by all (red), cardiotoxicity (blue bar) vs non‐cardiotoxicity (grey bar) and between all (red), epirubicin, paclitaxel, cyclophosphamide (light blue bar) and paclitaxel, non‐pegylated doxorubicin, carboplatin (light grey bar) group. Analysis is shown as mean±SD and independent samples t‐test shown by P values. The time points of assessment are baseline, after 6 weeks, and at the end of therapy. iddEPC indicates neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; and PM(Cb), paclitaxel, non‐pegylated doxorubicin, carboplatin.
Figure 4
Figure 4. High‐sensitivity cardiac troponin T during therapy.
A, High‐sensitivity cardiac troponin T (hsTrop T) (cardiotoxicity vs non‐cardiotoxicity); (B) High‐sensitivity cardiac troponin T (neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide vs paclitaxel, non‐pegylated doxorubicin, carboplatin). High‐sensitivity cardiac troponin T as assessed by all (red), cardiotoxicity (blue bar) vs non‐cardiotoxicity (grey bar) and between all (red), EPC (light blue bar) and PM(Cb) (light grey bar) group. Analysis is shown as mean±SD and independent samples t‐test shown by P values. The time points of assessment are baseline, after 6 weeks, and at the end of therapy. iddEPC indicates neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide; hsTrop T, high‐sensitivity cardiac troponin T; and PM(Cb), paclitaxel, non‐pegylated doxorubicin, carboplatin.
Figure 5
Figure 5. Hemoglobin during therapy.
A, Hemoglobin (cardiotoxicity vs non‐cardiotoxicity); (B) Hemoglobin (neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide vs paclitaxel, non‐pegylated doxorubicin, carboplatin). Hemoglobin as assessed by all (red), cardiotoxicity (blue bar) vs non‐cardiotoxicity (grey bar) and between all (red), EPC (light blue bar) and PM(Cb) (light grey bar) group. Analysis is shown as mean±SD and independent samples t‐test shown by P values. The time points of assessment are baseline, after 6 weeks, and at the end of therapy. iddEPC indicates neo‐adjuvant dose‐dense, dose‐intensified epirubicin, paclitaxel, and cyclophosphamide; and PM(Cb), paclitaxel, non‐pegylated doxorubicin, carboplatin.
See this image and copyright information in PMC

References

    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz‐Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al. Cardiovascular disease and breast cancer: where these entities intersect. A scientific statement from the American Heart Association. Circulation. 2018;137:e30–e66. - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre AL, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Ross JS, Fletcher JA. The HER‐2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–428. - PubMed
    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene. Science. 1987;235:177–182. - PubMed
    1. Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab‐induced cardiotoxicity in breast cancer: a meta‐analysis. Medicine (Baltimore). 2016;95:e5195. - PMC - PubMed

Publication types

MeSH terms

Associated data